←Back to Expert Scholars
Translational Medicine / 转化医学Breast Cancer, HR-Positive PI3K
Dejan Juric
MD
🏢Massachusetts General Hospital / Harvard Medical School🌐USA
Director, Henri and Belinda Termeer Center
55
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Dejan Juric leads early-phase clinical development of PI3K alpha inhibitors in HR-positive breast cancer and helped establish alpelisib in PIK3CA-mutant disease. He runs first-in-human trials of next-generation CDK and PI3K pathway agents. His work addresses post-CDK4/6 progression strategies.
Share:
🧪Research Fields 研究领域
PI3K alpha inhibitors
alpelisib SOLAR-1
post-CDK4/6 resistance
early phase breast trials
PIK3CA mutations
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Dejan Juric 的研究动态
Follow Dejan Juric's research updates
留下邮箱，当我们发布与 Dejan Juric（Massachusetts General Hospital / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment